Search Results - "Baird, Richard D"

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial by Schmid, Peter, Abraham, Jacinta, Chan, Stephen, Wheatley, Duncan, Brunt, Adrian Murray, Nemsadze, Gia, Baird, Richard D, Park, Yeon Hee, Hall, Peter S, Perren, Timothy, Stein, Robert C, Mangel, László, Ferrero, Jean-Marc, Phillips, Melissa, Conibear, John, Cortes, Javier, Foxley, Andrew, de Bruin, Elza C, McEwen, Robert, Stetson, Daniel, Dougherty, Brian, Sarker, Shah-Jalal, Prendergast, Aaron, McLaughlin-Callan, Max, Burgess, Matthew, Lawrence, Cheryl, Cartwright, Hayley, Mousa, Kelly, Turner, Nicholas C

“…The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib…”
Get full text

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial by Sandhu, Shahneen K, MD, Schelman, William R, MD, Wilding, George, MD, Moreno, Victor, MD, Baird, Richard D, PhD, Miranda, Susana, BSc, Hylands, Lucy, BSc, Riisnaes, Ruth, FIBMS, Forster, Martin, PhD, Omlin, Aurelius, MD, Kreischer, Nathan, MSc, Thway, Khin, MD, Gevensleben, Heidrun, MD, Sun, Linda, PhD, Loughney, John, PhD, Chatterjee, Manash, PhD, Toniatti, Carlo, PhD, Carpenter, Christopher L, MD, Iannone, Robert, MD, Kaye, Stan B, Prof, de Bono, Johann S, Prof, Wenham, Robert M

“…Summary Background Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective…”
Get full text

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors by YAP, Timothy A, LI YAN, RIISNAES, Ruth, POPE, Lorna L, HEATON, Simon P, THOMAS, George, GARRETT, Michelle D, SULLIVAN, Daniel M, DE BONO, Johann S, TOLCHER, Anthony W, PATNAIK, Amita, FEAREN, Ivy, OLMOS, David, PAPADOPOULOS, Kyriakos, BAIRD, Richard D, DELGADO, Liliana, TAYLOR, Adekemi, LUPINACCI, Lisa

“…AKT signaling is frequently deregulated in human cancers. MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in…”
Get full text

Genomic profile of advanced breast cancer in circulating tumour DNA by Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.

“…The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical…”
Get full text

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.

“…Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with…”
Get full text

Antitumor activity in RAS-driven tumors by blocking AKT and MEK by Tolcher, Anthony W, Khan, Khurum, Ong, Michael, Banerji, Udai, Papadimitrakopoulou, Vassiliki, Gandara, David R, Patnaik, Amita, Baird, Richard D, Olmos, David, Garrett, Christopher R, Skolnik, Jeffrey M, Rubin, Eric H, Smith, Paul D, Huang, Pearl, Learoyd, Maria, Shannon, Keith A, Morosky, Anne, Tetteh, Ernestina, Jou, Ying-Ming, Papadopoulos, Kyriakos P, Moreno, Victor, Kaiser, Brianne, Yap, Timothy A, Yan, Li, de Bono, Johann S

“…KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244;…”
Get full text

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer by Macpherson, Iain R, Spiliopoulou, Pavlina, Rafii, Saeed, Saggese, Matilde, Baird, Richard D, Garcia-Corbacho, Javier, Italiano, Antoine, Bonneterre, Jacques, Campone, Mario, Cresti, Nicola, Posner, John, Takeda, Yousuke, Arimura, Akinori, Spicer, James

“…Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour…”
Get full text

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.

Get full text

Weekly paclitaxel in the treatment of recurrent ovarian cancer by Kaye, Stan B, Baird, Richard D, Tan, David S. P

“…This Review discusses the advantages and disadvantages of weekly paclitaxel for the treatment of relapsed ovarian cancer. When compared with the 3 weekly…”
Get full text

Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA by Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.

Get full text

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation by Ang, Joo Ern, Pandher, Rupinder, Ang, Joo Chew, Asad, Yasmin J, Henley, Alan T, Valenti, Melanie, Box, Gary, de Haven Brandon, Alexis, Baird, Richard D, Friedman, Lori, Derynck, Mika, Vanhaesebroeck, Bart, Eccles, Suzanne A, Kaye, Stan B, Workman, Paul, de Bono, Johann S, Raynaud, Florence I

“…PI3K plays a key role in cellular metabolism and cancer. Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26…”
Get full text

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial by Turner, Nicholas C, Kingston, Belinda, Kilburn, Lucy S, Kernaghan, Sarah, Wardley, Andrew M, Macpherson, Iain R, Baird, Richard D, Roylance, Rebecca, Stephens, Peter, Oikonomidou, Olga, Braybrooke, Jeremy P, Tuthill, Mark, Abraham, Jacinta, Winter, Matthew C, Bye, Hannah, Hubank, Michael, Gevensleben, Heidrun, Cutts, Ros, Snowdon, Claire, Rea, Daniel, Cameron, David, Shaaban, Abeer, Randle, Katrina, Martin, Sue, Wilkinson, Katie, Moretti, Laura, Bliss, Judith M, Ring, Alistair

“…Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy…”
Get full text

Enhanced detection of circulating tumor DNA by fragment size analysis by Mouliere, Florent, Chandrananda, Dineika, Piskorz, Anna M, Moore, Elizabeth K, Morris, James, Ahlborn, Lise Barlebo, Mair, Richard, Goranova, Teodora, Marass, Francesco, Heider, Katrin, Wan, Jonathan C M, Supernat, Anna, Hudecova, Irena, Gounaris, Ioannis, Ros, Susana, Jimenez-Linan, Mercedes, Garcia-Corbacho, Javier, Patel, Keval, Østrup, Olga, Murphy, Suzanne, Eldridge, Matthew D, Gale, Davina, Stewart, Grant D, Burge, Johanna, Cooper, Wendy N, van der Heijden, Michiel S, Massie, Charles E, Watts, Colin, Corrie, Pippa, Pacey, Simon, Brindle, Kevin M, Baird, Richard D, Mau-Sørensen, Morten, Parkinson, Christine A, Smith, Christopher G, Brenton, James D, Rosenfeld, Nitzan

“…Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties…”
Get more information

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer by Glaviano, Antonino, Foo, Aaron S C, Lam, Hiu Y, Yap, Kenneth C H, Jacot, William, Jones, Robert H, Eng, Huiyan, Nair, Madhumathy G, Makvandi, Pooyan, Geoerger, Birgit, Kulke, Matthew H, Baird, Richard D, Prabhu, Jyothi S, Carbone, Daniela, Pecoraro, Camilla, Teh, Daniel B L, Sethi, Gautam, Cavalieri, Vincenzo, Lin, Kevin H, Javidi-Sharifi, Nathalie R, Toska, Eneda, Davids, Matthew S, Brown, Jennifer R, Diana, Patrizia, Stebbing, Justin, Fruman, David A, Kumar, Alan P

“…The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and…”
Get full text

Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data by Burdon, Abigail J, Baird, Richard D, Jaki, Thomas

“…Adaptive enrichment allows for pre-defined patient subgroups of interest to be investigated throughout the course of a clinical trial. These designs have…”
Get full text

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA by Hudecova, Irena, Smith, Christopher G, Hänsel-Hertsch, Robert, Chilamakuri, Chandra S, Morris, James A, Vijayaraghavan, Aadhitthya, Heider, Katrin, Chandrananda, Dineika, Cooper, Wendy N, Gale, Davina, Garcia-Corbacho, Javier, Pacey, Simon, Baird, Richard D, Rosenfeld, Nitzan, Mouliere, Florent

“…Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. Data supporting this view has been mainly acquired through…”
Get full text

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors by Baird, Richard D, Kitzen, Jos, Clarke, Paul A, Planting, Andre, Reade, Sarah, Reid, Alison, Welsh, Lyndsey, López Lázaro, Luis, de las Heras, Begona, Judson, Ian R, Kaye, Stan B, Eskens, Ferry, Workman, Paul, deBono, Johann S, Verweij, Jaap

“…A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics, and efficacy of ES-285, a novel agent isolated from a marine…”
Get full text

Genetic heterogeneity in breast cancer: the road to personalized medicine? by Baird, Richard D, Caldas, Carlos

“…More women die from breast cancer across the world today than from any other type of malignancy. The clinical course of breast cancer varies tremendously…”
Get full text

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer by Hamilton, Erika P, Patel, Manish R, Armstrong, Anne C, Baird, Richard D, Jhaveri, Komal, Hoch, Matthias, Klinowska, Teresa, Lindemann, Justin P O, Morgan, Shethah R, Schiavon, Gaia, Weir, Hazel M, Im, Seock-Ah

“…AZD9496 is an oral nonsteroidal, small-molecule inhibitor of estrogen receptor alpha (ERα) and a potent and selective antagonist and degrader of ERα. This…”
Get full text

Clinical development of new drug–radiotherapy combinations by Sharma, Ricky A., Plummer, Ruth, Stock, Julie K., Greenhalgh, Tessa A., Ataman, Ozlem, Kelly, Stephen, Clay, Robert, Adams, Richard A., Baird, Richard D., Billingham, Lucinda, Brown, Sarah R., Buckland, Sean, Bulbeck, Helen, Chalmers, Anthony J., Clack, Glen, Cranston, Aaron N., Damstrup, Lars, Ferraldeschi, Roberta, Forster, Martin D., Golec, Julian, Hagan, Russell M., Hall, Emma, Hanauske, Axel-R., Harrington, Kevin J., Haswell, Tom, Hawkins, Maria A., Illidge, Tim, Jones, Hazel, Kennedy, Andrew S., McDonald, Fiona, Melcher, Thorsten, O'Connor, James P. B., Pollard, John R., Saunders, Mark P., Sebag-Montefiore, David, Smitt, Melanie, Staffurth, John, Stratford, Ian J., Wedge, Stephen R.

“…The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) includes academia, industry, patient groups and…”
Get full text